Rain Oncology Shares Plummet: Company Discloses Disappointing Cancer Study Data After Delaying Readout

Rain Oncology Inc RAIN announced topline Phase 3 MANTRA data of milademetan in patients with dedifferentiated (DD) liposarcoma (LPS).

The study did not meet its primary endpoint of progression-free survival (PFS) by blinded independent central review compared to the standard of care, Johnson & Johnson's JNJ Yondelis (trabectedin).

Related: Anticipation Builds For Rain Oncology's Phase 3 MANTRA Trial Results, Analyst Sees Promise.

The median PFS for milademetan was 3.6 months vs. 2.2 months for trabectedin, with a hazard ratio of 0.89, p=0.53. 

The most common treatment-emergent adverse events (TEAEs) in the milademetan arm included nausea, thrombocytopenia, anemia, vomiting, and neutropenia.

The most common Grade 3/4 TEAEs were thrombocytopenia (39.5%), neutropenia (25.5%), and anemia (18.6%). 

Dose reductions in the milademetan arm were 44.2% vs. 29.1% in the trabectedin arm. 

Discontinuation in the milademetan arm due to AEs was 11.6% vs. 19.0% for trabectedin. 

Based upon these topline data, Rain does not expect to pursue further development of milademetan in DD LPS. 

Price Action: RAIN shares are down 86.9% at $1.30 on the last check Monday.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!